ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 226,04
0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Endo International PLC (ENDP)

  7. Endo International PLC (ENDP) Actualités

ENDP

Endo (ENDP)

Endo International PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ENDP
DateHeureSourceTitreSymboleSociété
21/09/202313h45PR Newswire (Canada)Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual MeetingNASDAQ:ENDPEndo International PLC
08/08/202313h45PR Newswire (US)ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
18/07/202322h30PR Newswire (US)Endo Launches Bivalirudin Injection in Ready-to-Use VialsNASDAQ:ENDPEndo International PLC
13/07/202322h30PR Newswire (US)Endo Presents New Data at the American Podiatric Medical Association Annual MeetingNASDAQ:ENDPEndo International PLC
29/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
12/06/202313h30PR Newswire (US)Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled SyringeNASDAQ:ENDPEndo International PLC
08/05/202313h30PR Newswire (US)ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
17/04/202313h45PR Newswire (US)Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label ProgramNASDAQ:ENDPEndo International PLC
03/04/202322h30PR Newswire (Canada)Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral SuspensionNASDAQ:ENDPEndo International PLC
13/03/202321h17PR Newswire (US)Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar FibromatosisNASDAQ:ENDPEndo International PLC
10/03/202313h30PR Newswire (US)Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) CapsulesNASDAQ:ENDPEndo International PLC
06/03/202322h14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ENDPEndo International PLC
27/02/202323h15Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ENDPEndo International PLC
27/02/202323h00Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:ENDPEndo International PLC
13/02/202318h39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ENDPEndo International PLC
06/02/202313h30PR Newswire (US)Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's DiseaseNASDAQ:ENDPEndo International PLC
31/01/202323h06Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:ENDPEndo International PLC
06/12/202222h45PR Newswire (US)Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)NASDAQ:ENDPEndo International PLC
09/11/202217h37Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ENDPEndo International PLC
27/10/202213h30PR Newswire (US)Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment ToolNASDAQ:ENDPEndo International PLC
07/10/202213h30PR Newswire (US)Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual MeetingNASDAQ:ENDPEndo International PLC
05/10/202213h30PR Newswire (US)Endo Launches Unscripted Video Series With Real Dupuytren's Contracture PatientsNASDAQ:ENDPEndo International PLC
08/09/202219h44Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ENDPEndo International PLC
17/08/202212h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ENDPEndo International PLC
17/08/202204h00PR Newswire (US)Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business TransformationNASDAQ:ENDPEndo International PLC
10/08/202220h08Dow Jones NewsEndo Bondholder Group Continues to Call on Company Not to File for BankruptcyNASDAQ:ENDPEndo International PLC
09/08/202215h00PR Newswire (US)New Drug Filing for Cenobamate Accepted for Review in Canada and IsraelNASDAQ:ENDPEndo International PLC
09/08/202214h45PR Newswire (US)ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
08/08/202222h30PR Newswire (Canada)Laboratoires Paladin inc. annonce que Santé Canada a accepté la demande d'autorisation de mise sur le marché des comprimés de cénobamate comme traitement d'appoint pour la prise en charge des crises partielles chez les adultes atteints d'épilepsieNASDAQ:ENDPEndo International PLC
08/08/202222h30PR Newswire (Canada)Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with EpilepsyNASDAQ:ENDPEndo International PLC
 Showing the most relevant articles for your search:NASDAQ:ENDP

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
LR
Legrand
COIN
BTCUSD
Bitcoin
EU
HO
Thales
EU
BNP
BNP Paribas
EU
ACA
Credit Agricole
NASDAQ
AAPL
Apple
EU
DG
Vinci
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
EU
RNO
Renault
EU
PX4
SBF 120
NYSE
NKE
Nike
EU
SGO
Cie de SaintGobain
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés